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chronic intestinal inflammation could be further strati-
fied according to immunological parameters and thus
have important implications for the design of individual-
ized therapies in IBD patients in the future. In particular,
one may envision that specific TLR- and IL-23-directed
therapies may be helpful for selective control of innate
and adaptive immune responses in some forms of IBD.
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Much has been learned since Jan Klein first defined
immunology as the ‘‘science of self non-self discrimi-
nation.’’ A paper in this issue of Immunity provides
important insight into how such discrimination is
achieved (Zehn and Bevan, 2006).
The generation of lymphocyte repertoires of immense
diversity has allowed vertebrates to survive challenges
from ever-evolving infectious agents. The cost of such
diversity, however, is the risk of generating immune
cells reactive to the individuals own tissues. Vertebrates
have limited this risk by evolving both central and
peripheral tolerance mechanisms. This is especially
important for T lymphocytes, because B lymphocytes
must be able to hypermutate their receptors for affinity
maturation.
Both CD4 and CD8 T cells differentiate in the thymus,
and the process of ‘‘central tolerance’’ weeds out many
potentially autoreactive cells. There seems little doubt,
however, that the thymus does not express all potential
self antigens. Nevertheless, there is clear evidence that
medullary thymic epithelial cells (mTECs) can express
antigens whose expression was previously thought to
be limited to specific organs. Importantly, expression
of many of these proteins is controlled by a single gene
called autoimmune regulatory (Aire) (Su and Anderson,
2004). Aire was first identified by mapping the gene
responsible for autoimmune polyendocrinopathy syn-
drome type 1 (APS-1) in humans. This disease is charac-
terized by the coincidence of two or three major clinicalsymptoms: Addison’s disease, hypoparathyroidism,
and chronic mucocutaneous candidiasis. APS-1 and
a similar disease found in Aire-deficient mice results
from the failure to delete developing self-targeting
thymocytes.
Many potentially autoreactive T cells escape deletion
in the thymus. There are various mechanisms that allow
CD4 cells to escape deletion (Anderton and Wraith,
2002). For example, T cells specific for the immunodo-
minant epitope of myelin basic protein (MBP) in H-2u
mice escape thymic deletion as a result of low-avidity
antigen recognition. Importantly, the T cell repertoire
of all human beings contains T cells that can readily be
activated with self-antigens, such as MBP, and yet auto-
immune disease associated with such cells is extremely
rare. This then points to the importance of peripheral
tolerance mechanisms.
Lederberg suggested that immature lymphocytes
contacting antigen would be subject to ‘‘clonal abor-
tion,’’ whereas mature cells would be activated. This
concept was supported by later studies showing that
T cells differentiating in the thymus were relatively sen-
sitive to antigen and would be deleted by amounts of
antigen less than the threshold required for activation
of the cells in the periphery (Pircher et al., 1991). Such
a mechanism would be fine for antigens present at simi-
lar or greater amounts in the thymus compared to the
periphery. But what about antigens not expressed in
the thymus or those whose expression in the periphery
could greatly exceed that in the thymus? Here peripheral
tolerance mechanisms would be required to maintain
tolerance. Deletion, anergy, sequestration/ignorance,
and immune regulation all play a part in this process.
Zehn and Bevan describe the Rip-mOva transgenic
mouse that expresses membrane bound ovalbumin in
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192the pancreatic b cells and in proximal tubules of the kid-
ney, as well as mTECs. They also employed a transgenic
mouse expressing only the b chain of the T cell receptor
(TCR) specific for the Kb-restricted ovalbumin peptide.
This mouse generates a broad repertoire of CD8 TCR of
varying affinity for the specific antigen. The use of F1
hybrids between these two mice and appropriate cell-
transfer experiments allowed Zehn and Bevan to com-
pare the influence of central and peripheral tolerance
mechanisms on this T cell repertoire. A further elegant
approach was to assess the affinity of T cells remaining
in the repertoire after tolerance induction. This tech-
nique involved nonspecific expansion of the T cells with
beads coated with antibodies to CD3 and CD28. After
a short expansion in vitro, the cells were challenged with
antigen over a broad concentration range, and intra-
cellular cytokine staining was used to detect IFN-g-
producing cells. This allowed a much clearer definition
of functional avidity selection during tolerance than
T cell staining with antigen-loaded tetramers.
Two important observations arose from this study.
First of all, T cell recognition in the thymus resulted in
deletion of cells bearing high-affinity TCR. Importantly,
however, deletion of cells by recognition of antigen in
the periphery appeared to be equally effective. This then
argues against the idea that T cells are more sensitive to
central or thymic mechanisms of deletion than they are
to similar mechanisms in the periphery. We must now
question whether immature cells are inherently more
sensitive to cell deletion in vivo or whether it is the rela-
tive amount of antigen expressed that dictates the bal-
ance between central and peripheral tolerance. Further
work will be required to define the amount of antigen ex-
posure, in terms of functional MHC-peptide complexes
on antigen-presenting cells (APC), required for central
versus peripheral tolerance in vivo. Given this, it will
be possible to categorically say whether mature lym-
phocytes are equally or less sensitive to deletion than
their immature counterparts.
Deletion would appear to be the most likely mecha-
nism of CD8 peripheral tolerance observed in this study.
Other workers have, however, noted additional mecha-
nisms such as anergy (Redmond and Sherman, 2005).
Furthermore, Singh and Schwartz have shown that
CD4 cells can change their sensitivity to antigen in vivo
(Singh and Schwartz, 2003). This could be an alternative
explanation for the peripheral tolerance noted by Zehn
and Bevan. Further analysis of TCR V a chain usage in
the repertoire of cells subjected to peripheral tolerance
should clarify this issue.
The significance of the Zehn and Bevan paper is 3-fold.
First, it emphasizes the role of avidity in defining the T cell
repertoire. Under normal circumstances, a repertoire
containing autoreactive cells recognizing self-antigen
with low avidity is consistent with a healthy immune sys-
tem. Second, their findings confirm the importance of
peripheral tolerance for CD8 cells. Such mechanisms
of deletion, in addition to anergy and adaptive tuning,
enable the immune system to maintain tolerance to anti-
gens not found in the thymus or expressed at higher
levels in the periphery than the thymus. Finally, periph-
eral tolerance mechanisms, such as those defined in
this paper, could contribute to tolerance or reduced
immunity toward neoantigens such as tumor antigens.Under normal circumstances, the amount of self-anti-
gen expressed in the individual remains below the
threshold for functional activation of low-avidity auto-
reactive T cells. What might alter this threshold? The
threshold for activation is controlled by the amount of
self-antigen available, the level of costimulatory mole-
cule expression on APC, and the activity of regulatory
cells controlling both APC maturation and lymphocyte
expansion.
In most cases, the precise trigger for autoimmune
conditions is unknown. Microbes are able to alter the
threshold for activation of low-avidity autoreactive T
cells and could trigger autoreactive cells by a variety
of mechanisms. The first is molecular mimicry. Thus,
any microbe expressing an epitope serving as a molec-
ular mimic for an autoantigen would have the potential
to induce disease. Crossreactive activation of autoreac-
tive T cells becomes even more plausible given that sin-
gle TCRs can recognize a broad spectrum of different
epitopes including peptides with totally different se-
quences (Hemmer et al., 2000). The fact that clear exam-
ples of molecular mimicry are so rare is therefore quite
remarkable (Benoist and Mathis, 2001).
The second mechanism is bystander activation (Hor-
witz et al., 1998). Microbial infections may damage
tissues, thereby releasing previously sequestered self-
antigens, may upregulate expression of costimulatory
molecules on self-antigen associated APC, and finally
might transiently suppress the function of regulatory T
cells, thereby allowing activation of low-avidity auto-
reactive T cells. Zehn and Bevan addressed this ques-
tion in two different ways. First, double transgenic mice
were infected with either lymphocytic choriomeningitis
virus or Listeria monocytogenes. Either type of infection
might be expected to induce bystander activation, but
this did not trigger autoimmune diabetes; nor did intro-
duction of ovalbumin-specific CD4 cells. Raising the an-
tigenic load, by infecting mice with Listeria monocyto-
genes-secreting ovalbumin, did, however, cross the
threshold, and the double transgenic mice suffered au-
toimmune diabetes. This implies that autoimmune dis-
ease can be triggered by raising the load of the specific
self-antigen although, in this case, the infection would
also have increased the potency of APC.
One could speculate that an infectious antigen mim-
icking a self-antigen would also trigger disease if the load
of antigen were sufficient to reach the activation thresh-
old of self-reactive cells. This may not be so straightfor-
ward, however, since the T cell repertoire specific for
a T cell epitope is further tuned to a fine avidity window
during the course of the immune response (Anderton,
2006). The threat of molecular mimicry is further blunted
by this mechanism. Avidity therefore plays an important
role in self non-self discrimination at three levels
(Figure 1). First, central tolerance is controlled by the
avidity of self-antigen recognition in the thymus. Second,
deletion of potentially autoreactive cells is similarly
controlled in the periphery. Third, the active immune re-
sponse to antigen is further governed by avidity. Taken
together, these mechanisms limit the threat of both
molecular mimicry and bystander activation. Finally, it
is important to emphasize that the threshold for activa-
tion of autoreactive cells is influenced by regulatory T
cells (Anderton, 2006). Hence, defects in molecules
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193Figure 1. T Cell Differentiation and Selection
Lead to Limitation of the Autoreactive T Cell
Repertoire
The repertoire of TCR specific for a given
epitope contains a range of receptors with
increasing affinity for antigen.
(A) If the epitope is presented in the thymus,
then this will lead to deletion of cells express-
ing a high-affinity TCR but will leave cells
expressing lower-affinity TCR.
(B) If the epitope is not presented in the thy-
mus, then cells expressing high-affinity TCR
may be deleted in the periphery.
(C) Some antigens may be expressed at
higher levels in the periphery than in the thy-
mus, leading to further peripheral deletion of
T cells.
(D) Cells with a suboptimal affinity for the an-
tigenic epitope fail to be selected during the
immune response to antigen.
(E) Cells with a high affinity for antigen are de-
leted during the immune response to antigen.controlling T-regulatory cell differentiation or function al-
low cells of an otherwise harmless T cell repertoire to
cause devastation.
In summary, the immune system has evolved various
mechanisms to limit the activation of autoreactive T
cells. The studies described by Zehn and Bevan in the
accompanying paper prove that the avidity of T cell rec-
ognition is a crucial determinant. Self non-self discrimi-
nation, i.e., health versus autoimmune disease, is main-
tained as long as autoreactive cells in the T cell
repertoire remain below the threshold for activation.
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